---
title: "Century Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286258453.md"
datetime: "2026-05-13T12:11:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286258453.md)
  - [en](https://longbridge.com/en/news/286258453.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286258453.md)
---

# Century Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.11.

EBIT: As of FY2026 Q1, the actual value is USD -25.7 M.

#### Collaboration Revenue

Century Therapeutics, Inc. reported no collaboration revenue for the quarter ended March 31, 2026, a decrease from $109.164 million for the same period in 2025.

#### Operating Expenses

Total operating expenses were $23.684 million for the quarter ended March 31, 2026, down from $34.988 million for the same period in 2025. **Research and Development (R&D) Expenses**: R&D expenses decreased to $17.1 million for the quarter ended March 31, 2026, compared to $26.6 million for the same period in 2025, primarily due to a reduction in personnel and lower clinical trial spending. **General and Administrative (G&A) Expenses**: G&A expenses were $6.6 million for the quarter ended March 31, 2026, down from $8.4 million for the same period in 2025.

#### Income (Loss) from Operations

The company reported an operating loss of - $23.684 million for the quarter ended March 31, 2026, compared to an operating income of $74.176 million for the same period in 2025.

#### Interest Income

Interest income was $2.019 million for the quarter ended March 31, 2026, compared to $2.422 million for the same period in 2025.

#### Other Income (Loss)

Other income was $0.020 million for the quarter ended March 31, 2026, compared to an other loss of - $0.038 million for the same period in 2025.

#### Net Income (Loss)

Century Therapeutics, Inc. reported a net loss of - $21.645 million for the quarter ended March 31, 2026, a significant change from a net income of $76.560 million for the same period in 2025.

#### Unrealized Loss on Investments

The unrealized loss on investments was - $0.615 million for the quarter ended March 31, 2026, compared to - $0.019 million for the same period in 2025.

#### Comprehensive Income (Loss)

Comprehensive loss was - $22.260 million for the quarter ended March 31, 2026, compared to a comprehensive income of $76.541 million for the same period in 2025.

#### Cash Flow and Position

Cash, cash equivalents, and marketable securities totaled $217.0 million as of March 31, 2026, an increase from $117.1 million as of December 31, 2025.Net cash used in operations was $25.3 million for the quarter ended March 31, 2026, an improvement from $34.6 million used in operations for the quarter ended March 31, 2025.

#### Operational Metrics and Pipeline Updates

Century Therapeutics, Inc. made progress in IND-enabling activities for CNTY-813, its type 1 diabetes iPSC-derived islet therapy, including non-clinical development, manufacturing, and regulatory readiness.The company remains on track to complete IND-enabling activities for CNTY-308, a CD19-targeted CAR-iT cell therapy, and initiate clinical testing in 2026, pending regulatory clearance.

#### Outlook / Guidance

Century Therapeutics, Inc. projects that its cash, cash equivalents, and investments as of March 31, 2026, will fund operations into the first quarter of 2029. The company expects to submit an IND for CNTY-813 in the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027. Additionally, the company aims to advance CNTY-308 into the clinic this year.

### Related Stocks

- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)

## Related News & Research

- [Gamehaus Holdings Inc. Announces Unaudited Financial Results for the Third Quarter of Fiscal 2026 Ended March 31, 2026 | GMHS Stock News](https://longbridge.com/en/news/289035965.md)
- [PowerFleet Q4 2026 Earnings Preview](https://longbridge.com/en/news/289616465.md)
- [Factorial Files Super 8-K Containing Q1 2026 Financial Results | FAC Stock News](https://longbridge.com/en/news/289602927.md)
- [Soybean Analysis: 2026 Market Volatility and Trend](https://longbridge.com/en/news/289444628.md)
- [Zedge Q3 2026 Earnings Preview](https://longbridge.com/en/news/289381005.md)